Device Trial Radar · NCT07720765
Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,050
Planned (sponsor's estimate)
Start
Oct 9, 2023
Primary completion
Apr 1, 2030
Study completion Apr 1, 2031
Sponsor
- Lead sponsor
- IRCCS San RaffaeleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 22, 2026
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
OCt.IN.N is a national, monocentric, prospective, observational cohort study evaluating the utility and applicability of Optical Coherence Tomography (OCT) in the diagnostic workup and longitudinal monitoring of neurological diseases. 840 patients with Central Nervous System neurological diseases (Multiple Sclerosis, Alzheimer's disease, Parkinson's disease, migraine/headache) and 210 age-matched healthy controls will undergo OCT examination at baseline and at 6, 12, 18, and 24 months of follow-up at IRCCS San Raffaele Hospital, Milan, Italy. OCT is a non-invasive, rapid, and reproducible technique that automatically measures the thickness of individual retinal layers. Retinal layer thicknesses and their longitudinal changes will be correlated with established clinical scales, neuroimaging, and biological markers used in routine neurological practice.
Conditions
- Multiple Sclerosis
- Alzheimer Disease
- Parkinson Disease
- Migraine
- Headache Disorders
Interventions
Optical Coherence Tomography (OCT) - Heidelberg SPECTRALIS HRA+OCTDevice
Spectral-domain Optical Coherence Tomography (OCT) performed using the Heidelberg SPECTRALIS HRA+OCT device (Class IIa CE-marked medical device). The procedure is non-invasive: the patient sits in front of the device and is asked to fix a target (light or cross) through a lens. No drugs or contrast agents are administered. OCT automatically acquires images of the macular region (where GCL and IPL are most represented) and the optic nerve head region (where RNFL is most represented), providing automated measurements of the thickness of individual retinal layers. OCT is performed at baseline and at follow-up visits at 6, 12, 18, and/or 24 months. Ophthalmological evaluation may be performed at the investigators' discretion if OCT images, clinical symptoms, or medical history suggest concurrent ocular pathology. Patients with a known diagnosis of epilepsy or history of epileptic seizures will not undergo specific imaging modes using clearly visible light sources (MultiColor, FA, BAF).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual rate of peripapillary RNFL thinning in patients with Multiple Sclerosis vs healthy controlsTime frame: Baseline, 6, 12, 18, and 24 months
- Annual rate of peripapillary RNFL thinning in patients with Alzheimer's Disease vs healthy controlsTime frame: Baseline, 6, 12, 18, and 24 months
- Annual rate of peripapillary RNFL thinning in patients with Parkinson's Disease vs healthy controlsTime frame: Baseline, 6, 12, 18, and 24 months
6 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
IRCCS Ospedale San Raffaele - Neurology and Neurophysiology Unit
Milan, Milano, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.